

Subject Index

- 5-flucytosine 142
- 5-fluorocytosine 23, 24
- 5-fluorocytosine, in vitro synergy 130
- academic medical center 79
- acute leukemia 156, 222
- acute respiratory distress syndrome (ARDS) 53
- acyclovir 25, 47, 156, 180
- adherence 104
- AIDS (acquired immunodeficiency syndrome) 147, 158, 219, 231, 238
- allogeneic bone marrow transplantation 2
- Ambisomes 132
 - tissue distribution 132
- amikacin resistance 241
- amphotericin B 23, 24, 60, 63, 73, 92, 117, 141, 228
 - acute toxicity 131
 - aerosol 128
 - daily dose in invasive aspergillosis 131
 - in vitro synergy 130
 - optimal duration of treatment 131
- amphotericin B lipid complexes (ABLC) 132
- antagonism 49
- antibody-related immunity 148
- antifungal prophylaxis 142
- antifungal therapy 85
 - combination 142
- antimicrobial susceptibility patterns 81
- ARDS (acute respiratory distress syndrome) 53
- aspergillosis
 - animal models 130
 - complicating chronic granulomatous disease 109
 - disseminated 118
 - enhancement of host defenses 133
 - granulocyte transfusion 133
 - groups at risk of 128
 - microbicidal response 109
 - primary sites 128
 - variables influencing outcome 131
- aspergillosis, invasive 109, 117
 - antigen detection 119
 - complicating granulocytopenia 109
 - complicating high-dose corticosteroid therapy 109
 - diagnosis of 118
 - endothelium 113
 - host defenses 110, 112
 - macrophages 109
 - management 130
 - monocytes 109
 - neutrophils 109
 - phagocyte function 109
 - pulmonary 118
 - rabbit model of 120
- Aspergillus* 109
 - animal studies 129
 - antibody 117
 - antigenemia 121
 - dissemination of 128
 - factors predisposing to infection with 23
 - mononuclear phagocytes (macrophages) 118
 - susceptibility tests (in vitro) 129

- Aspergillus* species
 correlation between MIC values and clinical outcome 130
 autoimmune disease 206
 autologous bone marrow transplantation 7, 98
 axillae 20
- B-cell 25
 bacteremia 30, 94, 231, 232
 bacterial pathogens 231
 bacterial translocation 20
Bacteroides fragilis 52
 β -lactam antibiotics 221
 β -lactam resistance 241
 β -lactamase, chromosomal 244
 β -lactamases, extended-spectrum 244
 biofilm (glycocalyx) 30
Blastocystis hominis 239
Blastoschizomyces capitatus 237
 bone marrow aspiration sites 20
 broad-spectrum antibacterial antibiotics 228
 broad-spectrum antimicrobial administration 23
 Broviac intravascular catheters 232
- Candida*, predisposing factors to 138
 candidemia, catheter-related 140
 candidiasis 23, 137
 disseminated 138
 acute 138
 chronic 138
 treatment of 141
 "capillary leak" syndrome 199
 ceftazidime 50, 52
 cell-mediated immunity 147, 177
 cellular immune dysfunction 25, 31
 cellular immune function, impaired 201
 central venous catheters 221
 chemotaxis 104
 chemotherapeutic agents 148
 chronic granulomatous disease 109
 ciprofloxacin 47, 53
 circulating *Aspergillus* antigen 117, 119
 detection of, latex agglutination method 121
 cisplatin 84
 clinical trials 249, 260
 antimicrobial prophylaxis 253
 cost effectiveness 254
 empiric antibiotic management 255
 in febrile neutropenic patients 251
 modifications 253
 response criteria 252
 specific infections 252
 unexplained fever 252
- CMV (see cytomegalovirus)
 coagulase-negative staphylococci 221
 colonization 224
 colonization resistance 17
 colony-stimulating factors 85, 97, 133, 143
 combination therapy 21, 24
 complement (C3) 29
 compromised host 91
 conditional regimens 197
 corticosteroids 148
 corynebacteria, Group JK 236
Corynebacterium jeikeium 221, 236
Cryptococcus neoformans 238
Cryptosporidia 238
Curvularia species 236
 cytokines 25, 27, 28, 104, 187, 199, 227
 cytomegalovirus (CMV) 46, 161, 201
 diagnosis 163
 PCR (polymerase chain reaction) 170
 ganciclovir 165, 169
 BAL (bronchoalveolar lavage) 167, 168
 CMV culture 167
 CMV interstitial pneumonia 170
 CMV pneumonia 167
 CMV seropositive transplant recipients 169
 future considerations 170
 prophylaxis 169
 prophylaxis on development of CMV interstitial pneumonia 166
 in patients without severe GVHD 167
 recommendations 169
 side effects 168
 virologic variables 167
 incidence in bone marrow transplantation 161
 infection 163
 in patients with graft-versus-host disease 163
 pathogenesis 161
 prevention 164
 acyclovir 165
 immunoglobulin 164
 cytosine arabinoside 53
- degranulation 105

- drug development 258
 - in treatment of cancer 258
 - in treatment of infectious diseases 258
- economic costs 85
- effector cells 97
- ELISA 118
- empiric antifungal therapy 61
- empiric antimicrobial therapy 89
- empiric therapies, selecting 21, 67
- engraftment 31, 32
- enteritis 153
- Enterobacter* species 52
- Enterococcus* species 233
- Escherichia coli* 46
- esophagitis 19
- European Organization for Research on Treatment of Cancer 91
 - International Antimicrobial Therapy Cooperative Group 252
- Exophiala pisciphila* 237
- fMLP (f-Met-Leu-Phe) 104
- f-Met-Leu-Phe (fMLP) 104
- fever 89
 - persistence of 22
 - unexplained 60, 69
- filamentous fungi 22
- fingersticks 20
- fluconazole 23, 24, 63, 142
- fungal infections 137
 - therapy 22
- fungal pathogens, colonization of
 - indwelling catheters 228
- Fusarium* species 236
- G-CSF 25, 59, 75, 97, 103
 - oxidative metabolism 106
 - “priming” 105
- GM-CSF 25, 59, 75, 97, 103
 - oxidative metabolism 106
 - “priming” 105
- galactomannan antigen 119
- ganciclovir 165
- Geotrichum* species 236
- graft-versus-host disease 4, 185, 197
 - acute 185
 - association of infection with herpes virus group 191
 - association of infections to 199
 - autologous 186
 - chronic 5, 185, 187, 189, 205
 - autoimmune neutropenia 193
 - immunoglobulin levels 193
 - clinical features 188
 - grading systems 188
 - histologic features 187
 - hyperacute 199
 - immunopathology 186
 - infection 189
 - fungal 190
 - viral 190
 - infection prophylaxis
 - antibacterial 194
 - protective isolation 194, 198
 - interleukin 2 (IL-2) 186
 - natural killer (NK) cells 186
 - time course 189
 - tumor necrosis factor (TNF) 187
- graft-versus-leukemia 5
- gram-negative bacteria 221
- gram-negative rods 232
- gram-positive cocci 92, 232
- gram-positive infection 71, 221
 - colonization 224
 - in patients undergoing bone marrow transplantation 226
 - superinfection 224
 - thrombosis 225
- gram-positive organisms,
 - vancomycin-resistant 245
- granulocyte colony-stimulating factor 25, 59, 75, 97, 103
- granulocyte-macrophage colony-stimulating factor 25, 59, 75, 97, 103
- granulocyte transfusion
 - in aspergillosis 133
- granulocytopenia 17, 23, 24, 118, 127, 137
 - chemotherapy-induced 222
 - persistence of 22
- Hansenula anomala* 237
- hematopoietic cytokines 59
- hematopoietic growth factors 10
- hematopoiesis 97
- hematopoietic growth factors 210
- hemorrhagic gastroenteritis 202
- hepatitis 152, 239
 - fibrosing cholestatic hepatitis 217
- hepatitis B 213, 214
 - acute immune suppression 216
 - characteristics 215
 - chronic immunosuppression 216
 - chronic infection 214

- hepatitis B continued
 - course in immunocompromised patients 215
 - phases 215
 - convalescence 215
 - high replicative 215
 - low replicative 215
 - treatment 217
- hepatitis C 217
 - characteristics 218
 - chronic 218
 - in acquired immunodeficiency syndrome (AIDS) 218
 - parenteral transmission 217
 - treatment 219
 - recombinant interferon alfa-2b 219
- hepatitis C virus 31, 32
- Herpes simplex 47, 155
- Hickman catheter 29, 232, 238
- HLA complex 3
- human immunodeficiency virus 238
- humoral immune deficiencies 29
- humoral immune deficiency 10
 - late bacterial infections in 205
- humoral immunity 148
- hyperalimentation 228
- hypogammaglobulinemia 26
- hyposplenism 206

- IgG subclasses, deficiency in 206
- IL-3 (interleukin-3) 97
- imipenem 50, 52
- imipenem resistance 245
- immune serum globulins 26
- Immunocompromised Host Society 253
- immunosuppressed host 175
- immunosuppression 215
- immunotherapy 227
- impaired cellular immune function 201
- indwelling catheters
 - colonization of
 - fungus pathogens 228
- infecting organisms 231
- infection
 - acquisition 24
 - associated with contamination 31
 - associated with humoral immune dysfunction 32
 - associated with infusions 30
 - associated with splenic dysfunction 32
 - central nervous system 150
 - brain abscess 152
 - diagnosis
 - lumbar spinal fluid 151
 - encephalitis 151
 - encephalomyelitis 151
 - meningitis 151
 - during aplastic phase 198
 - enteritis 153
 - hepatitis 153
 - iatrogenic causes of 30
 - in marrow transplant patients 31, 32
 - in neutropenic patients 231
 - major routes 24
 - pneumococcal 29
 - skin 152
 - tunnel 30
 - viral 198
- infectious diseases and medical oncology
 - convergences of 257
- inflammatory response
 - signs and symptoms 21
- inhibition ELISA 120
- interferon- γ 134
- interleukin 3 (IL-3) 97
- International Antimicrobial Therapy Cooperative Group 91
- intravascular catheters
 - Broviac 232
 - Hickman 232
- intravenous immunoglobulin (IVIG) 209
 - itraconazole 132, 142
 - absorption 132
- IVIG (intravenous immunoglobulin) 209

- ketoconazole 23, 24, 63
- Klebsiella pneumoniae* 46

- Legionella micdadei* 234
- Legionella pneumophila* 233, 234
- Legionella* species 233
- Leptotrichia buccalis* 233
- Leuconostoc* species 235
- leukopenia 99
- liver disease 213
 - diagnosis 213
 - fibrosing cholestatic hepatitis 217
- lymphohematopoietic system, ablation of 197
- lymphoma 156

- macrophage function, impaired 127
- management strategy 67
- marrow aplasia 222
- marrow purging 7

- medical oncology and infectious diseases
 - convergences of 257
- miconazole 23, 24
- microflora 197
- monotherapy 21, 49, 75
- mucositis 47, 227
- mycoses 73

- National Marrow Donor Program 4
- neurosurgical tumors 151
- neutropenia 45, 58, 69, 89, 100, 106, 231
- neutrophil function, defective 127
- new pathogens 31
- norfloxacin 53
- Nosema* species 239
- nystatin 25

- obstruction 16
- opsonizing antibody 26
- oral absorbable agents 25
- oral antibiotics 72
- oral nonabsorbable antibiotics 25
- overwhelming pneumococcal sepsis syndrome 29

- pathogens 20
- patient care-team 81
- Peliosis hepatis 238
- perianal lesions 19
- periodontitis, acute 19
- peripheral blood progenitor cells 8
- peripheral stem cell reconstitution 64
- phagocytes 103
- phagocytosis 104
- phase I trials 259
- phase II trials 259
- phase III trials 259
- Phialophora parasitica* 237
- phototherapy 210
- piperacillin 94
- pneumococcal bacteremia 28
- Pneumocystis carinii* 209, 238
- pneumonia 20
 - interstitial 201
- pneumonitis 150
 - broncho-alveolar lavage (BAL) 150
 - lung biopsy 150
 - pulmonary infiltrates 150
- polymorphonuclear neutrophils 103
- prethymic autocytoxic T cells 210
- progenitor cells 97
- prophylactic antibiotic therapy 85
- prophylaxis of varicella zoster virus infection 181
- protective environments 198
- Prototheca wickerhamii* 238
- protozoal microsporidia 239
 - Encephalitozoon cuniculi* 239
 - Encephalitozoon hellem* 239
 - Nosema* species 239
- Pseudallescheria boydii* 236
- Pseudomonas aeruginosa* 46, 52
- Pseudomonas putrefaciens* 233
- pulmonary infiltrates 150

- quinolone prophylaxis 228
- quinolone resistance 246

- radioimmunoassay (RIA) 119
- recombinant interferon alfa-2b 219
- resistance 31
- respiratory burst 105
- Rhodococcus equi* 235
- Rhodotorula rubra* 236
- rifampin 23, 24
- Rochalimaea henseli* 238

- scanning electron microscopy 30
- sepsis 90
- septic shock 45
- silastic catheters 58
- sinopulmonary mucosa 206
- sinusitis 20
- skin infection 152
- Staphylococcus aureus* 46, 233
 - methicillin-resistant 52, 246
- Staphylococcus epidermidis* 53, 233
- Streptococcus faecium* 52
- Streptococcus mitis* 53, 227
- Streptococcus pneumoniae* 206, 233
- Streptococcus* species 46
- Streptococcus viridans* 53
- superinfection 224
- supportive care 90
- suppressor macrophages 26
- surgery
 - in management of aspergillosis 133
- synergism 48

- T-cell 25
- T cells
 - prethymic autocytoxic 210
- TMP/SMX (trimethoprim/sulfamethoxazole) 47
- TNF (tumor necrosis factor) 98
- tazobactam 94

- third party payors 80
- thrombosis 225
- Trichosporon beigelii* 236
- trimethoprim, resistance 246
- trimethoprim/sulfamethoxazole 47
- tumor necrosis factor (TNF) 98

- vancomycin 53, 221
- vancomycin resistance 245
- varicella 177
- varicella zoster immune globulin 181
- varicella zoster virus 175
 - mortality 177
 - pneumonitis in 178
 - pneumonitis
 - lymphopenia 178
 - treatment
 - acyclovir 180
 - vidarabine 180
 - visceral dissemination 179
- venous access catheters 29, 221
 - Hickman catheter 29
 - infections associated with 20, 32
- vidarabine 180
- viral infections 198
- viridans streptococci 233
- virus 151
- VZIG (varicella zoster immune globulin) 181

- white cell transfusions 25

- Xanthomonas maltophilia* 52, 233

- yeasts 22

- Zygomycetes 237